Posted by Michael Wonder on 28 Jan 2023
Ipsen receives CHMP negative opinion for palovarotene as a treatment for fibrodysplasia ossificans progressiva in EU
27 January 2023 - Ipsen to request re-examination of CHMP opinion on palovarotene as a potential treatment for fibrodysplasia ossificans progressiva in the EU.
Ipsen announced today that the CHMP of the EMA has recommended not to grant marketing authorisation for investigational palovarotene as a treatment for the ultra rare bone disease, fibrodysplasia ossificans progressiva.
